Wire · opportunities
Plymouth Meeting Biotech Inovio Wins FDA Nod for What It Calls the First DNA Medicine
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 November 2026 · Fusion42 review
Inovio Pharmaceuticals based in Plymouth Meeting has received FDA accelerated approval for Voceryq, the first DNA medicine for recurrent respiratory papillomatosis (RRP). The treatment, priced at $460,000 for a full series, will launch in early 2027 targeting laryngologists in the US, with plans to expand into European and UK markets.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your biotech startup must prepare for market access challenges as the first DNA medicine gains FDA approval, setting precedent and opening reimbursement debates. Launch strategies including insurer engagements and specialist targeting in rare diseases now offer a blueprint to follow.
◆ Coverage
1 source · 4 Nov 2026
◆ Related on Wire
◆ Topics